SAT-303 In-vitro Inhibition Of Human Gastric Cancer Cell (nugc3) Line Growth By A Cocktail That Had Already Inhibited Human Melanoma And Liver Cancer Cell Lines Growth In-vitro

Abstract Disclosure: P. Ramaraj: None. Gastric cancer is the fifth most common cancer and the fifth leading cause of cancer-related deaths worldwide. It is notoriously difficult to treat and often resistant to conventional therapies. Given these challenges, we investigated the inhibitory effects of a specific compound cocktail on the in-vitro growth of a human gastric cancer cell line (NUGC3). Our previous work using human melanoma cell lines (BLM, 1205Lu, WM238) identified two effective combinations: (1) progesterone + RU-486 + curcumin, and (2) vitamin A + RU-486. These cocktails significantly inhibited melanoma cell growth. Subsequently, we tested both combinations on human liver cancer cells (HepG2), which also showed significant growth inhibition. Encouraged by these findings, we next tested the vitamin A + RU-486 on the NUGC3 gastric cancer cell line. This decision was driven by two motivations: (1) to determine if this combination could be effective in another cancer cell line, and (2) to explore an alternative approach to inhibiting NUGC3 cell growth, as our previous work using progesterone and DHEA showed no significant inhibitory effect (though RU-486 treatment did reduce cell growth to 72% at a concentration of 100 μM). NUGC3 cells were seeded in a 96-well plate overnight. The next day, they were incubated with vitamin A or RU-486 individually, or in combinations, using varying concentrations (vitamin A: 50, 75, 100 μM; RU-486: 10, 50, 100 μM). Cell viability was assessed 48 hours post-treatment using a MTT assay, and supernatants were collected for future ELISA array analysis. Vitamin A alone demonstrated a dose-dependent decrease in cell growth. RU-486 also showed significant inhibitory effects at 50 and 100 μM. Notably, the combination of vitamin A (75 μM) and RU-486 (50 μM) resulted in a 43.7% reduction in cell growth, surpassing the effect observed with RU-46 alone at 100 μM in previous experiments. Conclusion: The vitamin A + RU-486 cocktail significantly inhibited cell growth in human melanoma, liver, and now gastric cancer cell lines. These results support further investigation of this combination as a potential broad-spectrum anticancer therapy. Future studies will involve testing the combination on normal gastric cells for control comparisons and utilizing ELISA arrays to identify cytokines involved in growth regulation. Presentation: Saturday, July 12, 2025